Minocycline Protects against Rotenone-Induced Neurotoxicity Correlating with Upregulation of Nurr1 in a Parkinson’s Disease Rat Model
Open accessAbstract
The aim of this study was to investigate the effect of minocycline in rats with rotenone-induced Parkinson's disease (PD). The open field test was performed to determine the motor ability of the rats. Double immunofluorescence staining was used to detect the expression of tyrosine hydroxylase (TH) and Nurr1 in the substantia nigra (SN) of rats. The relative protein levels of TH, Nurr1, and the total- and phosphorylated-cAMP-response element binding protein (CREB) were determined by western blot analysis. The production of reactive oxygen species (ROS) and nitric oxide (NO) was detected by commercial kits. After exposure to rotenone for 28 days, rats exhibited decreased ambulation and rearing frequency and prolonged immobility time with loss of TH positive neurons in the SN. The phosphorylation levels of CREB and Nurr1 expression decreased significantly accompanied with the release of ROS and NO. Minocycline alleviated the motor deficits of rats lesioned by rotenone and elevated the expression of TH, as well as suppressing the release of ROS and NO in the SN. That was in line with the elevated phosphorylation levels of CREB and Nurr1 expression. In conclusion, our present study showed minocycline protected against neurotoxicity in a rotenone-induced rat model of PD, which was correlated with upregulation of Nurr1.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Minocycline molecular changes explain increased striatal dopamine levels and cognitive and locomotor improvements in zebrafish, mouse, and rat models.
“Of note, these molecular changes seem to explain the increased striatal dopamine levels as well as the cognitive and locomotor improvements observed in zebrafish, mouse, and rat models [259,260,264,268,269,270,271].”
From The Interplay between Gut Microbiota and Parkinson’s Disease: Implications on Diagnosis and Treatment (2022) · cites this paper as [271]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
1 retracted
Shah, S. Z. A., Zhao, D., Taglialatela, G., Khan, S. H., Hussain, T. A., Dong, H., Lai, M., Zhou, X., & Yang, L. (2017) · Neurotherapeutics · doi:10.1007/s13311-016-0500-0 · Cited by 18 · see citing works
RetractedKalia, L. V., & Lang, A. E. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61393-3 · Cited by 6,412 · see citing works
Poewe, W., Seppi, K., Tanner, C. M., Halliday, G. M., Brundin, P., Volkmann, J., Schrag, A.-E., & Lang, A. E. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.13 · Cited by 5,415 · see citing works
Chronic systemic pesticide exposure reproduces features of Parkinson's disease
Betarbet, R., Sherer, T., Mackenzie, G., Garcia-Osuna, M., Panov, A., & Greenamyre, J. (2000) · Nature Neuroscience · doi:10.1038/81834 · Cited by 3,797 · see citing works
Transcriptional regulation by the phosphorylation-dependent factor CREB
Mayr, B., & Montminy, M. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35085068 · Cited by 2,587 · see citing works
Pathogenesis of Parkinson disease—the gut–brain axis and environmental factors
Klingelhoefer, L., & Reichmann, H. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.197 · Cited by 598 · see citing works
Mutations in NR4A2 associated with familial Parkinson disease
Le, W., Xu, P., Jankovic, J. J., Jiang, H. F., Appel, S. H., Smith, R. G., & Vassilatis, D. K. (2002) · Nature Genetics · doi:10.1038/ng1066 · Cited by 488 · see citing works
The NINDS NET-PD Investigators (2006) · Neurology · doi:10.1212/01.wnl.0000201252.57661.e1 · Cited by 453 · see citing works
The role of Nurr1 in the development of dopaminergic neurons and Parkinson's disease
Jankovic, J., Chen, S., & Le, W. D. (2005) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2005.09.001 · Cited by 325 · see citing works
Self-citationKim, K., Kim, C., Hwang, D., Seo, H., Chung, S., Hong, S. J., Lim, J., Anderson, T., & Ole Isacson, A. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01671.x · Cited by 209 · see citing works
Kim, C., Han, B., Moon, J., Kim, D.-J., Shin, J. S., Rajan, S. S., Nguyen, Q. T., Sohn, M., Kim, W., Han, M.-J., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1509742112 · Cited by 195 · see citing works
Cellular and Molecular Basis of Neurodegeneration in Parkinson Disease
Zeng, X., Geng, W.-S., Jia, J., Chen, L., & Zhang, P.-P. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00109 · Cited by 194 · see citing works
Lee, B., Cao, R., Choi, Y., Cho, H., Rhee, A. D., Hah, C. K., Hoyt, K. R., & Obrietan, K. H. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05864.x · Cited by 167 · see citing works
Synaptic Therapy in Alzheimer's Disease: A CREB-centric Approach
Teich, A. F., Nicholls, R. E., Puzzo, D., Fiorito, J., Purgatorio, R., Fà, M., & Arancio, O. (2015) · Neurotherapeutics · doi:10.1007/s13311-014-0327-5 · Cited by 147 · see citing works
Weng, M., Xie, X., Liu, C., Lim, K., Zhang, C., & Li, L. (2018) · Parkinson s Disease · doi:10.1155/2018/9163040 · Cited by 114 · see citing works
Emerging Roles of CREB-Regulated Transcription Coactivators in Brain Physiology and Pathology
Saura, C. A., & Cardinaux, J. (2017) · Trends in Neurosciences · doi:10.1016/j.tins.2017.10.002 · Cited by 110 · see citing works
Tetracycline repurposing in neurodegeneration: focus on Parkinson’s disease
Bortolanza, M., Nascimento, G. C., Socías, S. B., Ploper, D., Chehín, R. N., Raisman‐Vozari, R., & Bel, E. A. D. (2018) · Journal of Neural Transmission · doi:10.1007/s00702-018-1913-1 · Cited by 105 · see citing works
The Anti-Inflammatory Role of Minocycline in Alzheimers Disease
Budni, J., Garcez, M. L., de Medeiros, J., Cassaro, E., Bellettini‐Santos, T., Mina, F., & Quevedo, J. (2016) · Current Alzheimer Research · doi:10.2174/1567205013666160819124206 · Cited by 90 · see citing works
Hidalgo, C. (2005) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2005.1759 · Cited by 71 · see citing works
Age-related changes in dopamine signaling in Nurr1 deficient mice as a model of Parkinson's disease
Zhang, L., Le, W., Xie, W., & Dani, J. A. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.03.022 · Cited by 65 · see citing works
Dixit, A., Srivastava, G., Verma, D., Mishra, M., Singh, P. K., Prakash, O., & Singh, M. P. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.03.019 · Cited by 64 · see citing works
Baluchnejadmojarad, T., Eftekhari, S.-M., Jamali-Raeufy, N., Haghani, S., Zeinali, H., & Roghani, M. (2017) · Experimental Gerontology · doi:10.1016/j.exger.2017.10.023 · Cited by 61 · see citing works
An Update on the Role of Nitric Oxide in the Neurodegenerative Processes of Parkinson's Disease
Jiménez‐Jiménez, F. J., Alonso‐Navarro, H., Herrero, M. T., García‐Martín, E., & Agúndez, J. A. G. (2016) · Current Medicinal Chemistry · doi:10.2174/0929867323666160812151356 · Cited by 60 · see citing works
Quintero, E. M., Willis, L., Singleton, R., Harris, N., Huang, P., Bhat, N., & Granholm, A.-C. (2006) · Brain Research · doi:10.1016/j.brainres.2006.03.104 · Cited by 58 · see citing works
Management of Parkinson Disease in 2017
Okun, M. S. (2017) · JAMA · doi:10.1001/jama.2017.7914 · Cited by 54 · see citing works
Hedya, S. A., Safar, M. M., & Bahgat, A. K. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-0923-1 · Cited by 54 · see citing works
Sousa, K. M., Mira, H., Hall, A. C., Jansson-Sjöstrand, L., Kusakabe, M., & Arenas, E. (2006) · Stem Cells · doi:10.1634/stemcells.2006-0238 · Cited by 43 · see citing works
Cai, Z., Xiao, M., He, W., & Zhao, Y. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s73836 · Cited by 41 · see citing works
Chronic mild stress augments MPTP induced neurotoxicity in a murine model of Parkinson's disease
Janakiraman, U., Manivasagam, T., Justin Thenmozhi, A., Dhanalakshmi, C., Essa, M. M., Song, B.-J., & Guillemin, G. J. (2017) · Physiology & Behavior · doi:10.1016/j.physbeh.2017.01.046 · Cited by 36 · see citing works
Nitric oxide mediates increased susceptibility to dopaminergic damage in Nurr1 heterozygous mice
Imam, S. Z., Jankovic, J. J., Ali, S. F., SKINNER, J. T., Xie, W., Conneely, O. M., & Le, W. (2005) · The FASEB Journal · doi:10.1096/fj.04-3362com · Cited by 30 · see citing works
Farshbaf, M. J., Forouzanfar, M., Ghaedi, K., Kiani‐Esfahani, A., Peymani, M., Nejati, A. S., Izadi, T., Karbalaie, K., Noorbakhshnia, M., Rahgozar, S., et al. (2016) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-016-2764-4 · Cited by 24 · see citing works
Burgos‐Ramos, E., Puebla‐Jiménez, L., & Arilla, E. (2008) · Life Sciences · doi:10.1016/j.lfs.2008.11.019 · Cited by 21 · see citing works
Verma, D., Singh, D. K., Gupta, S., Gupta, P., Singh, A., Biswas, J., & Singh, S. (2018) · NeuroToxicology · doi:10.1016/j.neuro.2018.01.006 · Cited by 18 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Minocycline in neurodegenerative and psychiatric diseases: An update
Romero‐Miguel, D., Lamanna‐Rama, N., Casquero‐Veiga, M., Gómez‐Rangel, V., Desco, M., & Soto‐Montenegro, M. L. (2020) · European Journal of Neurology · doi:10.1111/ene.14642 · Cited by 95 · see citing works
Varesi, A., Campagnoli, L. I. M., Fahmideh, F., Pierella, E., Romeo, M., Ricevuti, G., Nicoletta, M., Chirumbolo, S., & Pascale, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012289 · Cited by 88 · see citing works
Pathogenesis of α-Synuclein in Parkinson’s Disease: From a Neuron-Glia Crosstalk Perspective
Yi, S., Wang, L.-F., Wang, H., Ho, M., & Zhang, S.-P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314753 · Cited by 66 · see citing works
Dissecting the Relationship Between Neuropsychiatric and Neurodegenerative Disorders
Gupta, R. V., Advani, D., Yadav, D., Ambasta, R. K., & Kumar, P. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03502-9 · Cited by 58 · see citing works
The role of NURR1 in metabolic abnormalities of Parkinson’s disease
Al‐Nusaif, M., Yang, Y., Li, S., Cheng, C., & Le, W. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00544-w · Cited by 52 · see citing works
Khakha, N., Khan, H., Kaur, A., & Singh, T. G. (2023) · Pharmacological Reports · doi:10.1007/s43440-023-00526-9 · Cited by 41 · see citing works
Modulation of CREB and its associated upstream signaling pathways in pesticide-induced neurotoxicity
Narasimhamurthy, R. K., Andrade, D., & Mumbrekar, K. D. (2022) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-022-04472-7 · Cited by 38 · see citing works
Loss‐of‐Function Mutations in NR4A2 Cause Dopa‐Responsive Dystonia Parkinsonism
Wirth, T., Mariani, L., Bergant, G., Baulac, M., Habert, M., Drouot, N., Ollivier, E., Hodžić, A., Rudolf, G., Nitschké, P., et al. (2020) · Movement Disorders · doi:10.1002/mds.27982 · Cited by 37 · see citing works
Challenges of Repurposing Tetracyclines for the Treatment of Alzheimer’s and Parkinson’s Disease
Markulin, I., Matasin, M., Turk, V. E., & Salković-Petrisic, M. (2022) · Journal of Neural Transmission · doi:10.1007/s00702-021-02457-2 · Cited by 36 · see citing works
CREB Inactivation by HDAC1/PP1γ Contributes to Dopaminergic Neurodegeneration in Parkinson's Disease
Xu, X., He, X., Zhang, Z., Chen, Y., Li, J., Ma, S., Huang, Q., & Li, M. (2022) · Journal of Neuroscience · doi:10.1523/jneurosci.1419-21.2022 · Cited by 35 · see citing works
Lu, J., Hou, L., Zhang, D., Li, S., Ruan, Z., Zhang, X., Hong, J., & Wang, Q. (2021) · Journal of Inflammation Research · doi:10.2147/jir.s299927 · Cited by 34 · see citing works
Almohmadi, N. H., Al-Kuraishy, H. M., Al-Gareeb, A. I., Albuhadily, A. K., Abdelaziz, A. M., Jabir, M. S., Alexiou, A. T., Papadakis, M., & Batiha, G. E. (2025) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2025.111349 · Cited by 35 · see citing works
Ujvari, B., Pytel, B., Márton, Z., Bognár, M. A., Kovács, L. Á., Farkas, J. I., Gaszner, T., Berta, G., Kecskés, A., Kormos, V., et al. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02399-w · Cited by 32 · see citing works
Altharawi, A., Alharthy, K. M., Althurwi, H. N., Albaqami, F. F., Alzarea, S. I., Al-Abbasi, F. A., Nadeem, M. S., & Kazmi, I. A. (2022) · Molecules · doi:10.3390/molecules27217159 · Cited by 27 · see citing works
Alghamdi, A. M., Al-Abbasi, F. A., AlGhamdi, S. A., Fatima, F., Alzarea, S. I., & Kazmi, I. A. (2023) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2023.103656 · Cited by 18 · see citing works
Minocycline as a prospective therapeutic agent for cancer and non-cancer diseases: a scoping review
Rezaei, A., Moqadami, A., & Khalaj‐Kondori, M. (2023) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-023-02839-1 · Cited by 18 · see citing works
Abdelaziz, A. M., Rasheed, N. O. A., Zaki, H. F., Salem, H. A., & El‐Sayed, R. M. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113839 · Cited by 17 · see citing works
Okyere, S. K., Zeng, C., Dong, Y., & Hu, Y. (2020) · Venoms and Toxins · doi:10.2174/2666121701999201104163407 · Cited by 16 · see citing works
Kavuri, S., Sivanesan, S., Howell, M. D., Vijayaraghavan, R., & Rajadas, J. (2020) · World Journal of Neuroscience · doi:10.4236/wjns.2020.104021 · Cited by 14 · see citing works
Zaigham, S. B., & Paeng, D. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46080545 · Cited by 13 · see citing works
Nurr1 downregulation is caused by CREB inactivation in a Parkinson’s disease mouse model
Xu, X., He, X., Ma, S., Li, M., & Huang, Q. (2021) · Neuroscience Letters · doi:10.1016/j.neulet.2021.136045 · Cited by 13 · see citing works
Kumar, S., & Kumar, P. (2021) · Current Molecular Pharmacology · doi:10.2174/1874467214666210126113324 · Cited by 12 · see citing works
Umukoro, S., Ajayi, A. M., Ben‐Azu, B., Adeleke, P. A., Areelu, J., Orji, C., & Okubena, O. (2023) · Metabolic Brain Disease · doi:10.1007/s11011-023-01253-z · Cited by 7 · see citing works
NURR1 Deficiency Is Associated to Altered Microglial Phenotype in Male Mice
Montarolo, F., Thielens, S., Bové, M., Bertolotto, A., Tempia, F., & Hoxha, E. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-04787-8 · Cited by 7 · see citing works
Metabotropic glutamate receptors and nitric oxide in dopaminergic neurotoxicity
Bashkatova, V. G. (2021) · World Journal of Psychiatry · doi:10.5498/wjp.v11.i10.830 · Cited by 7 · see citing works
Rafeeq, M. M., Al-Abbasi, F. A., Afzal, M., Alharbi, K. S., Moglad, E. H. O., Al-Qahtani, S. D., Bukhari, H. A., Imam, F., Sayyed, N., & Kazmi, I. A. (2025) · Current Neuropharmacology · doi:10.2174/011570159x349553250126050134 · Cited by 6 · see citing works
Effects of levodopa on gut bacterial antibiotic resistance in Parkinson’s disease rat
Sheng, S., Li, X., Zhao, S., Zheng, C.-Q., & Zhang, F. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1122712 · Cited by 6 · see citing works
Modern Pharmacological Treatment of Parkinson's Disease : Reviving Known Drugs and New Perspectives
Lastovetskyi, I., Cytlau, B., Marczyk, Ł., Zdrojewska, K., Łach, A., Krupa, J. K., Lorkowska-Zawicka, B., & Bujak-Giżycka, B. (2024) · International Journal Of Pharmaceutical Research And Allied Sciences · doi:10.51847/twysubd6pp · Cited by 3 · see citing works
Rivadeneyra-Domínguez, E., Zamora-Bello, I., Juárez-Zaragoza, E. R., Rosales-Sánchez, Ó., Guillén-Ruiz, G., & Rodríguez‐Landa, J. F. (2025) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-025-04934-7 · Cited by 2 · see citing works
The multiple mechanisms of NR4A2 in neurological disorders and advances in targeted therapy research
Duan, K., Yang, C., Gao, D., Li, M., Chen, M., Li, H., Zeng, W., Zhao, L.-J., & Zhu, M. (2025) · Neurobiology of Disease · doi:10.1016/j.nbd.2025.107229 · Cited by 3 · see citing works
Ondrus, M., Fox, R. J., Peelen, E., Fonseca, J., Sciacca, V., Sánchez‐Gómez, I., Arend, J., Herrmann, A., Samcova, M., Gege, C., et al. (2026) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2026.2705509 · Cited by 1 · see citing works
Revisiting Parkinson’s Disease Treatment: Exploring Established Medications and Emerging Therapies
Brooks, D., Carter, A., Moore, E., & Grant, O. (2024) · Journal of Applied Pharmaceutical Technologies and Systems · doi:10.68159/i340840675 · Cited by 1 · see citing works
SHH, nurr1, pitx3, and en1 models for Parkinson's disease
Ameen, G., Fahmy, H. M., Gaber, A., Abbas, F. M., & Soliman, R. I. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-16128-5.00007-4
Kuter, K. Z., Chwastek, A. M., Paleczna, M., Kadłuczka, J., Kosmowska, B., Leonovich, I., Maciasz, W., Lenda, T., & Kula, J. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.16.659904
Bayoumy, N. A., Elkhoely, A. A., & Mohamed, S. K. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05019-z
Barve, M. V., Micov, V., Uddin, A., Gurubaran, A., Madasu, S., Hiray, A., Lien, C., Kelly, N., Sartori, M., Wang, R., et al. (2026) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6c00211
Dada, M. M., Adelodun, S. T., & AWOLUSI, O. E. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.10.13.758640
- Authors
- Sun, C., Wang, Y., Mo, M., Song, C., Wang, X., Chen, S., & Liu, Y.
- Affiliations
- Qilu Hospital of Shandong University (CN)
- Xuzhou Medical College (CN)
- First Affiliated Hospital of Guangzhou Medical University (CN)
- Corresponding author
- Liu, Yiming
- Venue
- BioMed Research International
- Publisher
- Wiley
- Published
- 2019-03-05
- Volume
- 2019
- Pages
- 1-7
- ISSN
- 1110-7243 (ISSN-L)
- 2314-6133
- 2314-6141
- PMC
- PMC6425343
- OpenAlex
- W2919075554
- Cited by
- 37
- References
- 33
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 5 · 2023: 6 · 2022: 8 · 2021: 4 · 2020: 4
- FWCI
- 2.71
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- BioMed Research International (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- National Natural Science Foundation of China (81501100, 81471292, BS2015YY041, 2014WSB20030)
- Natural Science Foundation of Shandong Province (81501100, 81471292, BS2015YY041, 2014WSB20030)
- Projects of Medical and Health Technology Development Program in Shandong province (81501100, 81471292, BS2015YY041, 2014WSB20030)
- Topics
- Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nuclear Receptors and Signaling
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- minocycline, rotenone, Parkinson's disease, neuroprotection, Nurr1, CREB phosphorylation, tyrosine hydroxylase, substantia nigra, reactive oxygen species, nitric oxide, motor impairment, neurotoxicity
- MeSH terms
- Animals, Male, Minocycline, Nitric Oxide, Rotenone, Substantia Nigra, Up-Regulation, Rats, Wistar, Parkinsonian Disorders, Rats, Nuclear Receptor Subfamily 4, Group A, Member 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
